|
|||||
|
|
Phase Ib dose-escalation study of the selective,noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies |
|
| Authors: | John N. Allan,Javier Pinilla-Ibarz,Douglas E. Gladstone,Krish Patel,Jeff P. Sharman,William G. Wierda,Michael Y. Choi,Susan M. O’ Brien,Mazyar Shadman,Matthew S. Davids,John M. Pagel,Habte A. Yimer,Renee Ward,Gary Acton,Pietro Taverna,Daniel L. Combs,Judith A. Fox,Richard R. Furman,Jennifer R. Brown |
| Abstract: | |
| Keywords: | |